Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labiana HealthXMAD:LAB -0.75%57 Receivables Turnover is 3.16 as of Dec. 2025. GuruFocus rates XMAD:LAB with a GF Score™ of 57/100 and a GF Value™ of €3.59 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 950 Drug Manufacturers companies, Labiana Health ranks better than 72.53% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Labiana Health's Revenue for the
six
months ended in Dec. 2025 was €35.98 Mil. Labiana Health's average Accounts Receivable for the
six
months ended in Dec. 2025 was €11.37 Mil.
Hence, Labiana Health's Receivables Turnover for the
six
months ended in Dec. 2025 was 3.16.
Labiana Health (XMAD:LAB) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Labiana Health Receivables Turnover Related Terms
Labiana Health Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Labiana Health's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:LAB vs ZTS, UTHR, VTRS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labiana Health Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labiana Health's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Labiana Health's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labiana Health (XMAD:LAB) has a Receivables Turnover of 3.16 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Labiana Health and its competitors. According to the industry distribution chart, Labiana Health ranks #261 out of 950 companies in the Drug Manufacturers industry, placing it in the top 27.5%.
Is Labiana Health's Receivables Turnover too high?
Labiana Health's current Receivables Turnover is 3.16. The Drug Manufacturers industry median Receivables Turnover is 5.07. Labiana Health's value of 3.16 is 37.7% below this industry median. Based on the distribution chart, Labiana Health ranks #261 out of 950 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Labiana Health has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labiana Health's Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labiana Health ranks #261 out of 950 companies for Receivables Turnover. This puts Labiana Health in the upper half of its industry. The industry median Receivables Turnover is 5.07. Labiana Health's value of 3.16 is 37.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labiana Health's current Receivables Turnover of 3.16 is 37.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Labiana Health and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labiana Health's current Receivables Turnover is 3.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labiana Health stock overvalued right now?
Based on GuruFocus' analysis, Labiana Health (XMAD:LAB) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.59, compared to a current price of €6.65 — trading 85.2% above its estimated fair value. The current Receivables Turnover is 3.16 and 37.7% below the Drug Manufacturers industry median of 5.07. Labiana Health's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Labiana Health (XMAD:LAB), the current Receivables Turnover is 3.16 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labiana Health (XMAD:LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Labiana Health stock appears to be overvalued.
The current stock price of €6.65 is trading 85.2% above its estimated GF Value™ of €3.59.
GuruFocus considers Labiana Health to be Significantly Overvalued.
Key valuation signals for XMAD:LAB:
Receivables Turnover: 3.16
GF Value™: €3.59 vs. price of €6.65 (85.2% above fair value)
Industry Position: 37.7% below the Drug Manufacturers median (#261 of 950)
No single metric tells the full story. See the XMAD:LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include a GMP manufacturer for EU animal and human health industries, a manufacturer specializing in sterile and lyophilized dosage forms, and a source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol. The company operates in two segment Animal Health and Human Health.
57GF Score
Get the complete analysis for XMAD:LAB
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:LAB has been successfully added to your 
